Abstract
Sycosis barbae (SB) is a chronic, potentially scarring alopecia that primarily affects the beard. We report a unique case of refractory SB in a 31-year-old male successfully treated with bimekizumab, a dual inhibitor of interleukin (IL)-17A and IL-17F. Significant clinical improvement was observed after the second injection, with complete remission achieved after 4 months, highlighting the potential of this novel therapeutic approach for SB.